The promising new Alzheimer’s drugs to watch
— and the far-out ideas that could reshape how we treat the disease
Story by firstname.lastname@example.org
- 2023 is expected to be a big year for research on Alzheimer’s treatments.
- One drug, called Leqembi, recently got a green light from the FDA.
- Others are expected to release data from mid- and late-stage trials soon.
After a string of failures over the past few decades, biotech companies seem to be returning to the difficult and elusive hunt for Alzheimer’s treatments.
Alzheimer’s disease affects roughly 6.5 million Americans, and there is no cure. For decades, drugs focused on treating the condition have languished in clinical trials, failing to show that they could treat or slow the progression of the disease.
But amid some positive news, companies focused on Alzheimer’s have said they’ve received an influx of investor interest. This month, the Food and Drug Administration granted accelerated approval for a new Alzheimer’s drug called Leqembi, developed by the Japanese pharmaceutical company Eisai and Biogen, a biotech company based in Cambridge, Massachusetts.